Evidence map›Paper›PMID 38535885›Full record

ArticleTropical medicine and infectious disease2024

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.

Wafa Ben Hamouda, Mariem Hanachi, Sonia Ben Hamouda, Wafa Kammoun Rebai, Adel Gharbi, Amor Baccouche, Jihene Bettaieb, Oussema Souiai, Mohamed Ridha Barbouche, Koussay Dellagi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine and infectious disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Wafa Ben HamoudaLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Mariem HanachiLaboratory of Bioinformatics, Biomathematics and Biostatistics LR16IPT09, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Sonia Ben HamoudaLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Wafa Kammoun RebaiLaboratory of Medical Parasitology, Biotechnologies and Biomolecules, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Adel GharbiLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Amor BaccoucheLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Jihene BettaiebLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Oussema SouiaiLaboratory of Bioinformatics, Biomathematics and Biostatistics LR16IPT09, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Mohamed Ridha BarboucheLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Koussay DellagiPasteur Network, Institut Pasteur, 75724 Paris, France.
Melika Ben AhmedLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.ORCID 0000-0002-3179-1648
Chaouki BenabdessalemLaboratory of Transmission, Control and Immunobiology of Infections, Institut Pasteur de Tunis, Tunis El Manar University, Tunis 1002, Tunisia.
Institut Pasteur de Tunis · TNInstitut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccination constitutes the best strategy against COVID-19. In Tunisia, seven vaccines standing for the three main platforms, namely RNA, viral vector, and inactivated vaccines, have been used to vaccinate the population at a large scale. This study aimed to assess, in our setting, the kinetics of vaccine-induced anti-RBD IgG and IgA antibody responses.

methodsUsing in-house developed and validated ELISA assays, we measured anti-RBD IgG and IgA serum antibodies in 186 vaccinated workers at the Institut Pasteur de Tunis over 12 months.

resultsWe showed that RNA vaccines were the most immunogenic vaccines, as compared to alum-adjuvanted inactivated and viral-vector vaccines, either in SARS-CoV-2-naïve or in SARS-CoV-2-experienced individuals. In addition to the IgG antibodies, the vaccination elicited RBD-specific IgAs. Vaccinated individuals with prior SARS-CoV-2 infection exhibited more robust IgG and IgA antibody responses, as compared to SARS-CoV-2-naïve individuals.

conclusionsAfter following up for 12 months post-immunization, we concluded that the hierarchy between the platforms for anti-RBD antibody-titer dynamics was RNA vaccines, followed by viral-vector and alum-adjuvanted inactivated vaccines.

Indexed as

COVID-19IgAIgGinactivated vaccineskineticsRNA vaccinesviral vector vaccines

Identifiers

PMID38535885
PMCPMC10975151
OpenAlexW4392745445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.